The publications contained in this archive section are provided for historical purposes only. The views expressed in the publications are those of their respective authors and do not reflect the views of NOXXON. NOXXON disavows any obligation to update or correct the information contained in these publications.

Menne J, Eulberg D, Beyer D, Baumann M, Saudek F, Valkusz Z, Więcek A, Haller H.
C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.
Nephrol Dial Transplant. 2016.
read article on oxfordjournals.org

Kalnins A, Thomas MN, Andrassy M, Müller S, Wagner A, Pratschke S, Rentsch M, Klussmann S, Kauke T, Angele MK, Bazhin AV, Fischereder M, Werner J, Guba M, Andrassy J.
Spiegelmer Inhibition of MCP-1/CCR2 - Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
Scand J Immunol. 2015, 82(2), 102.
read abstract on pubmed.gov

Oberthür D, Achenbach J, Gabdulkhakov A, Buchner K, Maasch C, Falke S, Rehders D, Klussmann S, Betzel C.
Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2.
Nature Commun. 2015, 6, 6923.
read article on nature.com

Haller H, Menne J, Baumann M, Eulberg D.
CCL2 Inhibition with Emapticap Pegol (NOX-E36) in Type 2 Diabetic Patients with Albuminuria.

ISN World Congress of Nephrology
2015, Cape Town
Poster

Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Möckel D, Baeck C, Hittatiya K, Eulberg D, Luedde T, Kiessling F, Trautwein C, Lammers T, Tacke F.
CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis.

Gut.
2014.
view PubMed abstract on ncbi.nlm.nih.gov

Baeck C, Wei X, Bartneck M, Fech V, Heymann F, Gassler N, Hittatiya K, Eulberg D, Luedde T, Trautwein C, Tacke F.
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice.

Hepatology
2014,59(3), 1060-72.
read abstract on wiley.com

Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, Gassler N, Huss S, Klussmann S, Eulberg D, Luedde T, Trautwein C, Tacke F.
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
GUT 2012, Vol. 61(3), 416-26.
view PubMed abstract on ncbi.nlm.nih.gov

Darisipudi MN, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ.
Dual Blockade of the Homeostatic Chemokine CXCL12 and the Proinflammatory Chemokine CCL2 Has Additive Protective Effects on Diabetic Kidney Disease.
Am J Pathol. 2011, Vol. 179(1), 116-24.
view PubMed abstract on ncbi.nlm.nih.gov

Sayyed, S. G., Gaikwad, A. B., Lichtnekert, J., Kulkarni, O. P., Eulberg, D., Klussmann, S., Tikoo, K. & Anders, H.-J.
Progessive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10.
Nephrol. Dial. Transplant. 2010, Vol. 25(6), 1811-7.
view PubMed abstract on ncbi.nlm.nih.gov

Sayyed, S. G., Hägele, H., Kulkarni, O. P., Endlich, K., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J.
Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes.
Diabetologia 2009, Vol. 52(11), 2445-2454.
view PubMed abstract on ncbi.nlm.nih.gov

Clauss, S., Gross, O., Kulkarni, O., Avila-Ferrufino, A., Radomska, E., Segerer, S., Eulberg, D., Klussmann, S., & Anders, H.-J.
Ccl2/Mcp-1 blockade reduces glomerular and interstitial macrophages but does not ameliorate renal pathology in collagen4A3-deficient mice with autosomal recessive Alport nephropathy.
J. Pathol. 2009, Vol. 218(1), 40-47.
view PubMed abstract on ncbi.nlm.nih.gov

Kulkarni, O., Eulberg, D., Selve, N., Zöllner, S., Allam, R., Pawar, R. D., Pfeiffer, S., Segerer, S., Klussmann, S., & Anders, H.-J.
Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice.

J. Pharmacol. Exp. Ther. 2009, Vol. 328(2), 371-377.
view PubMed abstract on ncbi.nlm.nih.gov

Maasch, C., Buchner, K., Eulberg, D., Vonhoff, S. & Klussmann, S.
Physicochemical stability of NOX-E36, a 40mer L‑RNA (Spiegelmer) for therapeutic applications.
Nucleic Acids Symp.Ser. 2008, No. 52, 61-62.
view PubMed abstract on ncbi.nlm.nih.gov

Ninichuk, V., Clauss, S., Kulkarni, O., Schmid, H., Segerer, S., Radomska, E., Eulberg, D., Buchner, K., Selve, N., Klussmann, S., & Anders, H.-J.
Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.
Am. J. Pathol. 2008, Vol. 172(3), 628-637.
view PubMed abstract on ncbi.nlm.nih.gov

Eulberg, D., Purschke, W., Anders, H.-J., Selve, N. & Klussmann, S.
Spiegelmer NOX-E36 for Renal Diseases.

Therapeutic Oligonucleotides 2008, Ed. Jens Kurreck, Biomolecular Sciences Series of the Royal Society of Chemistry (RSC).

Kulkarni, O., Pawar, R. D., Purschke, W., Eulberg, D., Selve, N., Buchner, K., Ninichuk, V., Segerer, S., Vielhauer, V., Klußmann, S., & Anders, H.-J.
Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.
J. Am. Soc. Nephrol. 2007, Vol. 18, 2350-2358.
view PubMed abstract on ncbi.nlm.nih.gov